What is the clinical evidence from this study?

Study design: Cohort. Population: Established ASCVD or type 2 diabetes on statin therapy (n=17376). Intervention: Moderately elevated lipoprotein(a) (>46.8 nmol/L) vs. Lower lipoprotein(a) tertile (<12.5 nmol/L). Primary outcome: Major adverse cardiovascular events (MACE), defined as non-fatal myocardial infarction (MI), non-fatal stroke, or cardiovascular (CV) mortality (20% higher risk, p=<0.01).

What question did this study set out to answer?

This research aims to evaluate the association of elevated lipoprotein(a) with cardiovascular risk in statin-treated patients.

June 6, 2026European Journal of Preventive Cardiology

Lipoprotein(a) and residual cardiovascular risk in statin-treated patients

Q: What are the key findings of this study?

Moderately elevated lipoprotein(a) (>46.8 nmol/L) was associated with a 20% higher risk of MACE compared to levels <12.5 nmol/L in statin-treated patients (p<0.01).

Q: What question did this study set out to answer?

This research aims to evaluate the association of elevated lipoprotein(a) with cardiovascular risk in statin-treated patients.

View Full Paper

Ask AI

Bookmark

Key result

Moderately elevated Lp(a) linked to ~20% higher MACE risk in statin-treated patients.

20% higher risk
P<0.01
n=17,376

Why the study?

Does moderately elevated Lp(a) increase the risk of MACE in statin-treated patients with ASCVD or type 2 diabetes?

Key Points

This research aims to evaluate the association of elevated lipoprotein(a) with cardiovascular risk in statin-treated patients.
Included 17,376 patients aged ≥45 with ASCVD or type 2 diabetes from the UK Biobank.
Compared CV outcomes between lower and upper lipoprotein(a) tertiles (<12.5 vs. >46.8 nmol/L) using adjusted Poisson regression models.
Employ generalized additive Cox models for continuous analysis of lipoprotein(a) and major adverse cardiovascular events.
The upper lipoprotein(a) tertile showed a 20% higher risk of major adverse cardiovascular events (MACE) (p<0.01).
There was a 27% increased risk of hospitalization for myocardial infarction (p<0.05) and a 34% higher rate of coronary revascularization (p<0.001).
Increased CV mortality was 30% higher in the upper lipoprotein(a) tertile (p<0.05), with a stronger effect seen in those without established ASCVD.

Study Design

Type

Cohort (n=17,376)

Structured PICO

Does moderately elevated Lp(a) increase the risk of MACE in statin-treated patients with ASCVD or type 2 diabetes?

Population

17,376 statin-treated patients aged ≥45 years with established ASCVD or type 2 diabetes from the UK Biobank.

Exposure

Upper Lp(a)-tertile (>46.8 nmol/L)

Comparator

Lower Lp(a)-tertile (<12.5 nmol/L)

Outcome

Major adverse cardiovascular events (MACE), defined as non-fatal myocardial infarction (MI), non-fatal stroke, or cardiovascular (CV) mortalitycomposite

Main Result

Effect estimate: 20% higher risk

p-value: p=<0.01

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Moderately elevated Lp(a) levels below current guideline thresholds are associated with increased residual cardiovascular risk in statin-treated patients, particularly those without established ASCVD.

Cite This Study

Oftadeh et al. (2026) conducted a cohort in Established ASCVD or type 2 diabetes on statin therapy (n=17,376). Moderately elevated lipoprotein(a) (>46.8 nmol/L) vs. Lower lipoprotein(a) tertile (<12.5 nmol/L) was evaluated on Major adverse cardiovascular events (MACE), defined as non-fatal myocardial infarction (MI), non-fatal stroke, or cardiovascular (CV) mortality (20% higher risk, p=<0.01). Moderately elevated lipoprotein(a) (>46.8 nmol/L) was associated with a 20% higher risk of MACE compared to levels <12.5 nmol/L in statin-treated patients (p<0.01).

synapsesocial.com/papers/6a23bb9a71a5da9775e77100 https://doi.org/10.1093/eurjpc/zwag296

View Full Paper

Ask AI

Bookmark

Lipoprotein(a) and residual cardiovascular risk in statin-treated patients

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Lipoprotein(a) and residual cardiovascular risk in statin-treated patients

Key Points

Study Design

Structured PICO

Main Result

Discussion

Implication

Cite This Study

Keep reading

Keep reading